Differential Proteomic Analysis of Hepatocellular Carcinomas from Knockout Mice and Normal (Knockout) Livers

Overview

Journal Cancer Genomics Proteomics

Specialties Biochemistry
Genetics
Oncology

Date 2020 Oct 25

PMID 33099469

Citations 5

Authors

Caroline Lambrecht

Gabriela Bomfim Ferreira

Judit Domenech Omella

Louis Libbrecht

Rita De Vos

Rita Derua

Chantal Mathieu

Lut Overbergh

Etienne Waelkens

Veerle Janssens

Affiliations

Soon will be listed here.

Abstract

Background: Hepatocellular carcinoma (HCC) is the major type of primary liver cancer. Mice lacking the tumor-suppressive protein phosphatase 2A subunit B56δ (Ppp2r5d) spontaneously develop HCC, correlating with increased c-MYC oncogenicity.

Materials And Methods: We used two-dimensional difference gel electrophoresis-coupled matrix-assisted laser desorption/ionization time-of-flight mass spectrometry to identify differential proteomes of livers from wild-type, non-cancerous and HCC-affected B56δ knockout mice.

Results: A total of 23 proteins were differentially expressed/regulated in liver between wild-type and non-cancerous knockout mice, and 119 between non-cancerous and HCC knockout mice ('cancer proteins'). Overlap with our reported differential transcriptome data was poor. Overall, 56% of cancer proteins were reported before in HCC proteomics studies; 44% were novel. Gene Ontology analysis revealed cancer proteins mainly associated with liver metabolism (18%) and mitochondria (15%). Ingenuity Pathway Analysis identified 'cancer' and 'gastrointestinal disease' as top hits.

Conclusion: We identified several proteins for further exploration as novel potential HCC biomarkers, and independently underscored the relevance of Ppp2r5d knockout mice as a valuable hepatocarcinogenesis model.

Citing Articles

Genetic Analyses of Primary Liver Cancer Cell Lines: Correspondence With Morphological Features of Original Tumors.

Akiba J, Ogasawara S, Yano H Cancer Genomics Proteomics. 2024; 21(3):260-271.

PMID: 38670592 PMC: 11059599. DOI: 10.21873/cgp.20445.

Comprehensive analysis of the protein phosphatase 2A regulatory subunit B56ε in pan-cancer and its role and mechanism in hepatocellular carcinoma.

Wu H, Huang Y, Xu Y, Xiang W, Yang C, Liu R World J Gastrointest Oncol. 2024; 16(2):475-492.

PMID: 38425404 PMC: 10900161. DOI: 10.4251/wjgo.v16.i2.475.

A Novel Mouse Model of Combined Hepatocellular-Cholangiocarcinoma Induced by Diethylnitrosamine and Loss of .

Omella J, Cortesi E, Verbinnen I, Remmerie M, Wu H, Cubero F Cancers (Basel). 2023; 15(16).

PMID: 37627221 PMC: 10453342. DOI: 10.3390/cancers15164193.

2D-DIGE Analysis of Liver Disease in Mice.

Callebaut A, Derua R, Overbergh L, Janssens V Methods Mol Biol. 2022; 2596:231-244.

PMID: 36378443 DOI: 10.1007/978-1-0716-2831-7_17.

RNA splicing: a dual-edged sword for hepatocellular carcinoma.

Kashyap A, Tripathi G, Tripathi A, Rao R, Kashyap M, Bhat A Med Oncol. 2022; 39(11):173.

PMID: 35972700 DOI: 10.1007/s12032-022-01726-8.

References

Llovet J, Montal R, Sia D, Finn R . Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018; 15(10):599-616. DOI: 10.1038/s41571-018-0073-4. View

Lee J, Chu I, Mikaelyan A, Calvisi D, Heo J, Reddy J . Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet. 2004; 36(12):1306-11. DOI: 10.1038/ng1481. View

Lambrecht C, Libbrecht L, Sagaert X, Pauwels P, Hoorne Y, Crowther J . Loss of protein phosphatase 2A regulatory subunit B56δ promotes spontaneous tumorigenesis in vivo. Oncogene. 2017; 37(4):544-552. DOI: 10.1038/onc.2017.350. View

Teramoto R, Minagawa H, Honda M, Miyazaki K, Tabuse Y, Kamijo K . Protein expression profile characteristic to hepatocellular carcinoma revealed by 2D-DIGE with supervised learning. Biochim Biophys Acta. 2008; 1784(5):764-72. DOI: 10.1016/j.bbapap.2008.02.011. View

Albrethsen J, Miller L, Novikoff P, Angeletti R . Gel-based proteomics of liver cancer progression in rat. Biochim Biophys Acta. 2011; 1814(10):1367-76. DOI: 10.1016/j.bbapap.2011.05.018. View

Janssens V, Goris J . Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J. 2001; 353(Pt 3):417-39. PMC: 1221586. DOI: 10.1042/0264-6021:3530417. View

Marin J, Macias R, Monte M, Romero M, Asensio M, Sanchez-Martin A . Molecular Bases of Drug Resistance in Hepatocellular Carcinoma. Cancers (Basel). 2020; 12(6). PMC: 7352164. DOI: 10.3390/cancers12061663. View

Schulze K, Imbeaud S, Letouze E, Alexandrov L, Calderaro J, Rebouissou S . Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015; 47(5):505-511. PMC: 4587544. DOI: 10.1038/ng.3252. View

Minagawa H, Yamashita T, Honda M, Tabuse Y, Kamijo K, Tsugita A . Comparative analysis of proteome and transcriptome in human hepatocellular carcinoma using 2D-DIGE and SAGE. Protein J. 2008; 27(7-8):409-19. DOI: 10.1007/s10930-007-9123-y. View

10.

Sia D, Villanueva A, Friedman S, Llovet J . Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis. Gastroenterology. 2017; 152(4):745-761. DOI: 10.1053/j.gastro.2016.11.048. View

11.

Megger D, Rosowski K, Ahrens M, Bracht T, Eisenacher M, Schlaak J . Tissue-based quantitative proteome analysis of human hepatocellular carcinoma using tandem mass tags. Biomarkers. 2016; 22(2):113-122. DOI: 10.1080/1354750X.2016.1210678. View

12.

Kimura K, Ojima H, Kubota D, Sakumoto M, Nakamura Y, Tomonaga T . Proteomic identification of the macrophage-capping protein as a protein contributing to the malignant features of hepatocellular carcinoma. J Proteomics. 2012; 78:362-73. DOI: 10.1016/j.jprot.2012.10.004. View

13.

Louis J, Martens E, Borghgraef P, Lambrecht C, Sents W, Longin S . Mice lacking phosphatase PP2A subunit PR61/B'delta (Ppp2r5d) develop spatially restricted tauopathy by deregulation of CDK5 and GSK3beta. Proc Natl Acad Sci U S A. 2011; 108(17):6957-62. PMC: 3084077. DOI: 10.1073/pnas.1018777108. View

14.

Moon W, Yu H, Chung M, Kang M, Lee D . Pale bodies in hepatocellular carcinoma. J Korean Med Sci. 2000; 15(5):516-20. PMC: 3054682. DOI: 10.3346/jkms.2000.15.5.516. View

15.

Heindryckx F, Colle I, Van Vlierberghe H . Experimental mouse models for hepatocellular carcinoma research. Int J Exp Pathol. 2009; 90(4):367-86. PMC: 2741148. DOI: 10.1111/j.1365-2613.2009.00656.x. View

16.

Rebouissou S, Nault J . Advances in molecular classification and precision oncology in hepatocellular carcinoma. J Hepatol. 2020; 72(2):215-229. DOI: 10.1016/j.jhep.2019.08.017. View

17.

Corona G, De Lorenzo E, Elia C, Simula M, Avellini C, Baccarani U . Differential proteomic analysis of hepatocellular carcinoma. Int J Oncol. 2009; 36(1):93-9. View

18.

Thorgeirsson S, Lee J, Grisham J . Functional genomics of hepatocellular carcinoma. Hepatology. 2006; 43(2 Suppl 1):S145-50. DOI: 10.1002/hep.21063. View

19.

Sandgren E, Quaife C, Pinkert C, Palmiter R, Brinster R . Oncogene-induced liver neoplasia in transgenic mice. Oncogene. 1989; 4(6):715-24. View

20.

Schulze K, Nault J, Villanueva A . Genetic profiling of hepatocellular carcinoma using next-generation sequencing. J Hepatol. 2016; 65(5):1031-1042. DOI: 10.1016/j.jhep.2016.05.035. View